Synergistic compositions

Patent metadata

Field	Value
Publication number	US-10315993-B2
Application number	US-201815962498-A
Country	US
Kind code	B2
Filing date	Apr 25, 2018
Priority date	Jul 5, 2013
Publication date	Jun 11, 2019
Grant date	Jun 11, 2019

Abstract

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.

First claim

The invention claimed is:

1. A synergistic composition comprising a compound of formula I(a)

wherein ‘M + ’ represents calcium, magnesium, sodium, potassium, zinc, and lithium; and one or more thiazolidinediones.

2. The synergistic composition as claimed in claim 1 , wherein the thiazolidinedione is pioglitazone.

3. A method for the treatment of dyslipidemia, hypertriglyceridemia and diabetes mellitus comprising administering an effective, non-toxic and pharmaceutically acceptable amount of a compound of formula I(a)

wherein ‘M + ’ represents calcium, magnesium, sodium, potassium, zinc, and lithium; and one or more thiazolidinediones, to a mammal in need thereof.

4. A pharmaceutical composition comprising a compound of formula I(a)

wherein ‘M + ’ represents calcium, magnesium, sodium, potassium, zinc, and lithium; one or more thiazolidinediones; and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition as claimed in claim 4 , wherein the pharmaceutical composition can be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations.

6. The pharmaceutical composition as claimed in claim 4 , wherein the pharmaceutically acceptable excipient is selected from suitable binding agents, fillers, lubricants, glidants, disintegrants and wetting agents.

7. The pharmaceutical composition as claimed in claim 4 , wherein the pharmaceutical composition is in the form of a unit dose.

8. The synergistic composition as claimed in claim 1 , wherein the thiazolidinedione is rosiglitazone.

9. The synergistic composition as claimed in claim 1 , wherein the thiazolidinedione is selected from troglitazone, ciglitazone, and englitazone.

10. The method as claimed in claim 3 , wherein the thiazolidinedione is pioglitazone.

11. The method as claimed in claim 3 , wherein the thiazolidinedione is rosiglitazone.

12. The method as claimed in claim 3 , wherein the thiazolidinedione is selected from troglitazone, ciglitazone, and englitazone.

13. The pharmaceutical composition as claimed in claim 4 , wherein the thiazolidinedione is pioglitazone.

14. The pharmaceutical composition as claimed in claim 4 , wherein the thiazolidinedione is rosiglitazone.

15. The pharmaceutical composition as claimed in claim 4 , wherein the thiazolidinedione is selected from troglitazone, ciglitazone, and englitazone.

Assignees

• Cadila Healthcare Ltd

Inventors

• Jain Mukul R
• Giri Suresh
• Kothari Himanshu M
• Banerjee Kaushik
• Kachhiya Rashmikant

Classifications

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D207/333 Primary

  Radicals substituted by oxygen or sulfur atoms · CPC title